Onyx Pharmaceuticals (ONXX) 42.19 0.41

Onyx Pharmaceuticals, Inc.
(ONXX) 42.19 0.41

Last Trade:	42.19	Day Range:	42.01 - 42.5699
Trade Time:	12:02PM	52wk Range:	27.17 - 46.07
Prev. Close:	41.78	Market Cap:	2.68B
Open:	42.27	Div Yield:	0
Volume:	271393	PE:	-170
EPS:	-2.49

The Latest On ONXX

Morgan Stanley Initiates Coverage on Onyx Pharmaceuticals at Underweight, Announces PT of $38 2/10/12 6:42am

Rodman & Renshaw Maintains Outperform, $57 PT on ONYX Pharmaceuticals 1/23/12 10:32am

Rodman & Renshaw Maintains Outperform, $57 PT on Onyx 1/18/12 8:16am

Brean Murray Carret Reiterates Hold on Onyx on CORRECT Trial Data 1/18/12 7:32am

Rodman & Renshaw Maintains Outperform, $57 Target on ONYX Pharmaceuticals 1/17/12 9:14am

UPDATE: Jefferies Downgrades Onyx Pharmaceuticals to Hold 1/3/12 2:01pm

Jefferies Downgrades Onyx Pharmaceuticals to Hold 1/3/12 6:22am

Goldman Sachs Positive on Onyx Pharmaceuticals After Brivanib Failure 12/23/11 9:36am

Rodman & Renshaw Maintains Outperform, $57 PT on ONYX Pharmaceuticals 12/23/11 9:09am

Benzinga's M&A Chatter for Thursday December 15, 2011 12/15/11 5:47pm

Goldman Sachs Upgrades Onyx Pharmaceuticals to CL-Buy 12/15/11 5:57am

Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals Announce Multi-Year Collaboration 12/14/11 9:01am

Morgan Stanley Initiates Coverage on Onyx Pharmaceuticals at Underweight, Announces PT of $38 2/10/12

Rodman & Renshaw Maintains Outperform, $57 PT on ONYX Pharmaceuticals 1/23/12

Rodman & Renshaw Maintains Outperform, $57 PT on Onyx 1/18/12

Brean Murray Carret Reiterates Hold on Onyx on CORRECT Trial Data 1/18/12

Rodman & Renshaw Maintains Outperform, $57 Target on ONYX Pharmaceuticals 1/17/12

UPDATE: Jefferies Downgrades Onyx Pharmaceuticals to Hold 1/3/12

Jefferies Downgrades Onyx Pharmaceuticals to Hold 1/3/12

Goldman Sachs Positive on Onyx Pharmaceuticals After Brivanib Failure 12/23/11

Rodman & Renshaw Maintains Outperform, $57 PT on ONYX Pharmaceuticals 12/23/11

Benzinga's M&A Chatter for Thursday December 15, 2011 12/15/11

Goldman Sachs Upgrades Onyx Pharmaceuticals to CL-Buy 12/15/11

Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals Announce Multi-Year Collaboration 12/14/11

Benzinga's M&A Chatter for Thursday December 15, 2011 12/15/11

Puts Purchased on Onyx Pharmaceuticals (ONXX) 1/5/11

Calls Purchased on Onyx Pharmaceuticals (ONXX) 11/8/10

Upside Purchased on Onyx Pharmaceuticals (ONXX) 10/1/10

Top 5 Percentage Gainers On NASDAQ (CSR, ZZ, SFI, IDT, GGC) 7/26/10

Benzinga’s Volume Movers (MNTA, ONXX, IDSA, GENZ) 7/26/10

Mid-Day Market Movers (ASTC, SOCB, ONXX, CART) 7/26/10

Onyx Pharma Pops; Puts Sold (ONXX) 7/26/10

Benzinga’s Top Pre-Market NASDAQ Gainers (ONXX, AONE, GENZ, MLNX) 7/26/10

Afternoon Market Update 7/8/10

Afternoon Market Update 6/14/10

Benzinga’s Top Pre-Market Losers (ONXX, WYNN, AKAM, APC) 6/14/10

Morgan Stanley Initiates Coverage on Onyx Pharmaceuticals at Underweight, Announces PT of $38 2/10/12

Rodman & Renshaw Maintains Outperform, $57 PT on ONYX Pharmaceuticals 1/23/12

Rodman & Renshaw Maintains Outperform, $57 PT on Onyx 1/18/12

Brean Murray Carret Reiterates Hold on Onyx on CORRECT Trial Data 1/18/12

Rodman & Renshaw Maintains Outperform, $57 Target on ONYX Pharmaceuticals 1/17/12

UPDATE: Jefferies Downgrades Onyx Pharmaceuticals to Hold 1/3/12

Jefferies Downgrades Onyx Pharmaceuticals to Hold 1/3/12

Goldman Sachs Positive on Onyx Pharmaceuticals After Brivanib Failure 12/23/11

Rodman & Renshaw Maintains Outperform, $57 PT on ONYX Pharmaceuticals 12/23/11

Goldman Sachs Upgrades Onyx Pharmaceuticals to CL-Buy 12/15/11

Brean Murray Carret & Company Maintains Hold on Onyx Pharmaceuticals 12/14/11

UPDATE: Jefferies Maintains Buy, Lowers PT to $45 on Onyx 12/13/11

Trade ONXX
NOW!

Partner Headlines

Research Analyst's New Ratings ( AKS, RKT, ONXX, GILD, CELG, BIIB, BEAV, AVEO, AMGN, IDIX ) 2/10/12

FDA OKs Millennium's Velcade Injection 1/23/12

Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger 1/20/12

5 Inexpensive Stocks for Your Portfolio 1/18/12

Onyx Colon Cancer Drug Juggles Survival Benefit With Serious Side Effects 1/18/12

Biotech Lessons Learned From JPM 2012 1/13/12

ONYX Pharmaceuticals Inc. (ONXX) CFO Matthew K Fust sells 1,789 Shares 1/10/12

J.P. Morgan Biotech Confab Live Chat 1/9/12

Press Releases

Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results Teleconference and Webcast 2/9/12 Newswire Story

MethylGene Announces the Appointment of Dr. Henry J. Fuchs to its Board of Directors 2/2/12 Marketwire Story

Phase 3 Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapies 1/17/12 Newswire Story

Onyx Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference 1/3/12 Newswire Story

Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals Announce Multi-Year Collaboration to Accelerate Personalized Medicine Approaches for Multiple Myeloma 12/14/11 Newswire Story

Onyx Pharmaceuticals Presents Carfilzomib Data at 53rd American Society of Hematology Annual Meeting 12/12/11 Newswire Story

Onyx Pharmaceuticals Announces FDA Standard Review Designation of Carfilzomib New Drug Application for the Treatment of Relapsed and Refractory Multiple Myeloma 12/11/11 Newswire Story

Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting 12/10/11 Newswire Story

Onyx Pharmaceuticals to Host a Teleconference to Reprise Key Data From the American Society of Hematology Meeting 12/6/11 Newswire Story

Critical Alerts For Visa, Corning, ARM Holdings, Onyx Pharmaceuticals, and Hansen Natural Released By Seven Summits Research 11/29/11 Newswire Story

Onyx Pharmaceuticals Announces FDA Acceptance of New Drug Application for Carfilzomib for the Treatment of Relapsed and Refractory Multiple Myeloma 11/29/11 Newswire Story

Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting 11/7/11 Newswire Story

Get the latest ONXX stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Onyx Pharmaceuticals, Inc. stock price.

Onyx Pharmaceuticals, Inc. by YCharts